Predictmedix AI Announces Successful Clinical Validation at the University of Raharja, Indonesia, Demonstrating 95% Accuracy in Vital Sign Detection

Rhea-AI Summary

Predictmedix AI Inc. (CSE:PMED)(OTCQB:PMEDF)(FRA:3QP) proudly announces the results of a clinical validation conducted in collaboration with the University of Raharja in Indonesia. The study focused on developing AI-based software to capture vital signs like heart rate, respiration rate, body temperature, and blood pressure. The rigorous testing phase involved scanning approximately 6,000 subjects, resulting in a remarkable 95% accuracy across critical parameters. Predictmedix AI emphasizes data security, ensuring the system does not capture recognizable facial images. The Company will be issuing 350,000 common shares and 150,000 warrants as consideration for services provided by a consultant.

Positive

• The clinical validation represents a significant advancement in AI technology's role in enhancing safety culture and prioritizing individuals' well-being.
• The study's focus on developing AI-based software with a non-invasive approach to capture vital signs demonstrates Predictmedix's commitment to privacy and confidentiality.
• The remarkable 95% accuracy across critical parameters and the continuous refinement of AI algorithms highlight the reliability, consistency, and accuracy of Predictmedix AI's solution in vital sign readings.

Negative

• None.

TORONTO, ON / ACCESSWIRE / November 14, 2023 / Predictmedix AI Inc. (CSE:PMED)(OTCQB:PMEDF)(FRA:3QP) (the "Company" or "Predictmedix"), a leading provider of rapid health screening solutions powered by proprietary artificial intelligence (AI) is proud to announce the results of a clinical validation conducted in collaboration with the esteemed University of Raharja in Indonesia. Clinical validation represents a major stride in advancing AI technology's role in enhancing safety culture and prioritizing the well-being of individuals.

Key Objectives of the Clinical Study:

• Foster a culture of "Fit for Duty" and prioritize the mental and physical well-being of students.
• Facilitate joint research and development efforts leading to joint authorship of research papers between Predictmedix and Raharja University.
• Aggregate vital datasets to continually train and refine AI models for predictive patterns and valuable insights.

Scope of the Clinical Study:

The study focused on developing AI-based software with external support, emphasizing a non-invasive approach to capture vital signs like heart rate, respiration rate, height, body temperature, and blood pressure. Notably, no recognizable facial images were captured to maintain confidentiality and privacy

Predictmedix AI's Solution Features:

• Face Detection & Single Lively Face
• SOP Violation Detection (e.g., closed eyes, side face, mask on, glasses on)
• Body Temperature Detection
• Heart Rate Monitoring
• Respiration Rate Monitoring
• SpO2 Measurement
• Height Assessment
• Blood Pressure Measurement

Achievements and Accuracy:

The rigorous testing phase involved scanning approximately 6,000 subjects, resulting in a remarkable 95% accuracy across critical parameters. The AI algorithms undergo continuous refinement, ensuring reliability, consistency, and accuracy in vital sign readings.

Security and Privacy:

Predictmedix AI emphasizes data security, ensuring the system does not capture recognizable facial images, and safeguarding personal identity.

Iterative Refinements:

The validation process includes iterative refinements, ensuring the AI accuracy gap is less than 4%, and achieving an accuracy range between 90% and 99% for all vital signs.

"The clinical validation with Raharja University is a pivotal milestone in fostering a 'Fit for Duty' culture. We envision safer and more efficient workplaces globally. The accuracy and maturity of our AI solution, especially in vital sign screening, are truly rewarding. We eagerly anticipate exploring broader applications to benefit society" commented Dr. Rahul Kushwah, Chief Operating Officer of Predictmedix AI.

Raharja University endorses Predictmedix's Safe Entry Station (SES) solution, noting its effectiveness in non-invasive patient screening for various conditions.

The Company will be issuing 350,000 common shares and 150,000 warrants with each warrant exercisable into a common share for 2 years at an exercise price of $0.10 per share, as consideration for the services provided by a consultant to the Company. The shares will be subject to a hold period of 4 months from the date of issuance.

To receive company news, please sign up for alerts at the bottom of the page link below: https://predictmedix.com/press-releases/

About Predictmedix AI Inc.

Predictmedix AI Inc. (CSE:PMED)(OTCQB:PMEDF)(FRA:3QP) is an emerging provider of rapid health screening and remote patient care solutions globally. The Company's Safe Entry Stations - powered by a proprietary artificial intelligence (AI) - use multispectral cameras to analyze physiological data patterns and predict a variety of health issues including 19 physiological vital parameters, impairment by drugs or alcohol, fatigue, or various mental illnesses. Predictmedix AI's proprietary remote patient care platform empowers medical professionals with a suite of AI-powered tools to improve patient health outcomes. To learn more, please visit our website at www.Predictmedix.com or follow us on Twitter, Instagram or LinkedIn.

Public Relations Contact

For further media information or to set up an interview, please contact:

Nelson Hudes
Communications International (905) 660 9155
Nelson@hudescommunications.com
Dr. Rahul Kushwah (647) 889 6916

Caution Regarding Forward-Looking Information:

This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results of the Company. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances. The Company's securities have not been registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or "U.S. Persons", as such term is defined in Regulations under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful. Additionally, there are known and unknown risk factors which could cause the Company's actual results, performance or achievements to be materially different from any Page 4 of 4 future results, performance or achievements expressed or implied by the forward-looking information contained herein, such as, but not limited to dependence on obtaining regulatory approvals; the ability to obtain intellectual property rights related to its technology; limited operating history; general business, economic, competitive, political, regulatory and social uncertainties, and in particular, uncertainties related to COVID-19; risks related to factors beyond the control of the Company, including risks related to COVID-19; risks related to the Company's shares, including price volatility due to events that may or may not be within such party's control; reliance on management; and the emergency of additional competitors in the industry.

All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except required by law.

Disclaimer: "The Company is not making any express or implied claims that its product has the ability to diagnose, eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus) at this time.

THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED NOR DOES IT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

SOURCE: Predictmedix AI Inc.

View source version on accesswire.com:
https://www.accesswire.com/803021/predictmedix-ai-announces-successful-clinical-validation-at-the-university-of-raharja-indonesia-demonstrating-95-accuracy-in-vital-sign-detection

FAQ

What are the key objectives of the clinical study conducted by Predictmedix AI Inc. with the University of Raharja in Indonesia?

The key objectives were to foster a 'Fit for Duty' culture and prioritize the mental and physical well-being of students, as well as to facilitate joint research and development efforts leading to joint authorship of research papers between Predictmedix and Raharja University.

What features does Predictmedix AI's solution offer for health screening?

The solution offers face detection, SOP violation detection, body temperature detection, heart rate monitoring, respiration rate monitoring, SpO2 measurement, height assessment, and blood pressure measurement.

What achievements and accuracy were reported from the rigorous testing phase of the clinical study?

The study involved scanning approximately 6,000 subjects, resulting in a remarkable 95% accuracy across critical parameters. The AI algorithms undergo continuous refinement, ensuring reliability, consistency, and accuracy in vital sign readings.

What is the Company's consideration for the services provided by a consultant?

The Company will be issuing 350,000 common shares and 150,000 warrants, with each warrant exercisable into a common share for 2 years at an exercise price of $0.10 per share, as consideration for the services provided by a consultant.